VORELOXIN DNA-Intercalating Drug Topoisomerase II Inhibitor Oncolytic

被引：2

作者：

Moualla, H. ^{[1
]}

Mills, D. A. ^{[1
]}

Hromas, R. ^{[1
]}

Verschraegen, C. F. ^{[1
]}

机构：

[1] Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA

来源：

DRUGS OF THE FUTURE | 2009年 / 34卷 / 05期

关键词：

AG-7352; SNS-595; SPC-595; FORMERLY SNS-595;

D O I：

10.1358/dof.2009.034.05.1370796

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Voreloxin (SNS-595) is being developed by Sunesis Pharmaceuticals under license from Dainippon Sumitomo Pharmo for the treatment of a variety of solid and hematological malignancies. Voreloxin is a naphthyridine derivative that acts partly by inhibition of topoisomerase II causing replication-dependent DNA damage in the S-phose of the cell cycle and leading to apoptosis via irreversible G2 arrest. The drug has activity as monotherapy in recurrent acute myelogenous leukemic (AML) and in platinum-refractory ovarian cancer. The predominant dose-limiting toxicity is neutropenia. Voreloxin is now being tested in combination with other cytotoxic agents in patients with AML.

引用

页码：363 / 374

页数：12

共 50 条

[41] A novel Cu(II)-based DNA-intercalating agent: Structural and biological insights using biophysical and in silico techniques
Movahedi, Elaheh
Razmazma, Hafez
Rezvani, Alireza
Nowroozi, Alireza
Ebrahimi, Ali
Eigner, Vaclav
Dusek, Michal
Arjmand, Farukh
SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY, 2023, 293
[42] Cyclometalated DNA-Intercalating ruthenium(II) complexes that target cancer cell nuclei and exhibit high anticancer activities
Chao, Hui
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY, 2014, 19 : S735 - S736
[43] The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine
Walsby, Elisabeth J.
Coles, Steven J.
Knapper, Steven
Burnett, Alan K.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (03): : 393 - 399
[44] TAS-103 -: Oncolytic topoisomerase inhibitor
不详
DRUGS OF THE FUTURE, 2000, 25 (05) : 540 - 541
[45] ALKYL-LINKED DIQUINOLINES ARE MONOFUNCTIONAL AT-SELECTIVE DNA-INTERCALATING AGENTS
MCFADYEN, WD
DENNY, WA
WAKELIN, LPG
FEBS LETTERS, 1988, 228 (02) : 235 - 240
[46] TAS-103 - BMS-247615 - Oncolytic - Topoisomerase I/II inhibitor
不详
DRUGS OF THE FUTURE, 2001, 26 (05) : 514 - 515
[47] DNA-Binding by analogs of the left-half of azinomycin: A minimal DNA-intercalating structure
Szekely, Joseph
Zang, Hong
Shipman, Michael
Gates, Kent S.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 234
[48] The influence of lipophilicity on binding of boronated DNA-intercalating compounds in human glioma spheroids
Gedda, L
Ghaneolhosseini, H
Nilsson, P
Nyholm, K
Pettersson, J
Sjöberg, S
Carlsson, J
ANTI-CANCER DRUG DESIGN, 2000, 15 (04): : 277 - 286
[49] DNA binding by analogues of the left-half of azinomycin: A minimal DNA-intercalating structure.
Szekely, Joseph
Zang, Hong
Shipman, Michael
Gates, Kent S.
CHEMICAL RESEARCH IN TOXICOLOGY, 2007, 20 (12) : 2000 - 2000
[50] DNA cleavage by the Cu(II) complex of the DNA-intercalating 9-bis(pyridin-2-ylmethyl)aminobenzo[b]quinolizinium
Tian, Maoqun
Ihmels, Heiko
Broetz, Elke
DALTON TRANSACTIONS, 2010, 39 (35) : 8195 - 8202

← 1 2 3 4 5 →